Lack of genetic counseling referrals in women diagnosed with breast cancer contribute to a gap between the need for and completion of genetic testing, reducing access to more personalized therapies for these patients.

Alpelisib activity improves real-world progression-free survival in breast cancer patients with PIK3CA mutations when used in combination with fulvestrant compared with fulvestrant alone.

Research indicates no significant improvement in breast cancer–specific survival in male breast cancer in the past 30 years.

Prognostic understanding may be associated with hospitalization or hospice use depending on how patients were queried about their prognosis and whether oncologists’ estimates were considered.

Electronic patient-reported outcome remote monitoring of patients receiving parenteral cancer therapy in routine clinical care is feasible. Office intervention may reduce the need for emergency and inpatient services.